From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Glycopyrrolate cream for hyperhidrosis is typically formulated at a strength of 2%, which is the most commonly prescribed concentration for topical application, as supported by the most recent study 1. The cream is usually applied once or twice daily to affected areas such as the palms, soles, face, or axillae (underarms). When using glycopyrrolate cream, it should be applied to completely dry skin and allowed to absorb fully before covering the area. Patients should start with the lower concentration and increase as needed based on response and tolerability. This medication works by blocking acetylcholine receptors, which inhibits the activation of sweat glands. Some key points to consider when using glycopyrrolate cream for hyperhidrosis include:
- Side effects may include dry mouth, blurred vision, urinary retention, and local skin irritation, as reported in studies 1, 2.
- These side effects are typically mild and dose-dependent.
- Patients should avoid applying the cream to broken or irritated skin and should wash hands thoroughly after application unless treating the hands themselves.
- Results are usually noticeable within a few days of consistent use, though optimal effects may take 1-2 weeks to develop, as shown in the study 1. The most recent and highest quality study 1 compared the efficacy and safety of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial hyperhidrosis treatment, and found that both modalities showed complete response in 75% of cases, with a longer duration of action in the botulinum toxin group. Other studies, such as 2, also support the use of 2% glycopyrrolate cream for the treatment of axillary bromhidrosis, with statistically significant improvements in malodor and Hyperhidrosis Disease Severity Scale scores. Overall, the current evidence suggests that 2% glycopyrrolate cream is a effective and safe treatment option for hyperhidrosis, with a favorable side effect profile and significant improvements in symptoms and quality of life, as supported by the most recent study 1.